Scientific Literature
-
Health-related Quality of Life in Patients with β-Thalassemia: Data from the Phase 3 BELIEVE Trial of Luspatercept
Background: Patients with transfusion-dependent (TD) β-thalassemia require long-term red blood cell transfusions (RBCTs) that lead to iron overload, impacting health-related quality of life (HRQoL). Methods: The impact of luspatercept, a…
Read More » -
Longitudinal study of ICET-A on Glucose Tolerance, Insulin Sensitivity and β-cell Secretion in Eleven β-Thalassemia Major Patients with Mild Iron Overload
Background: Iron chelation therapy (ICT) is the gold standard for treating patients with iron overload, though its long-term effects are still under evaluation. According to current recommendations regarding transfusion-dependent (TD)…
Read More » -
Treating Chronic Pain in Sickle Cell Disease: The Need for a Biopsychosocial Model
Chronic pain is the most common complication affecting adults with sickle cell disease (SCD). Pain profoundly affects people’s quality of life, functional ability, and health care utilization. Clinicians are often…
Read More » -
Management of Luspatercept Therapy in Patients with Transfusion-dependent β-Thalassaemia
Patients with transfusion-dependent β-thalassaemia require lifelong, regular red blood cell transfusions for survival; however, frequent blood transfusions are associated with an increased risk of iron overload, transfusion-transmitted disease and alloimmunization,…
Read More » -
Applications of Αrtificial Ιntelligence in Τhalassemia: A Comprehensive Review
Thalassemia is an autosomal recessive genetic disorder that affects the beta or alpha subunits of the hemoglobin structure. Thalassemia is classified as a hypochromic microcytic anemia and a definitive diagnosis…
Read More » -
Deferiprone for Transfusional Iron Overload in Sickle Cell Disease and Other Anemias: Open-label Study of Up to 3 Years
Long-term safety and efficacy data on the iron chelator deferiprone in sickle cell disease (SCD) and other anemias are limited. FIRST-EXT was a 2-year extension study of FIRST (Ferriprox in…
Read More » -
Multi-Parametric Cardiac Magnetic Resonance for Prediction of Heart Failure Death in Thalassemia Major
We assessed the prognostic value of multiparametric cardiovascular magnetic resonance (CMR) in predicting death from heart failure (HF) in thalassemia major (TM). We considered 1398 white TM patients (30.8 ±…
Read More » -
A Novel, Effective, and Efficient Strategy for Treating Sickle Cell Vaso-occlusive Events in the Infusion Center Setting
A hypercoagulable state, chronic inflammation, and increased risk of venous thrombosis and stroke are prominent features in patients with sickle cell disease (SCD). Coagulation factor XII (FXII) triggers activation of…
Read More » -
Reduction in Vaso-Occlusive Events Following Hematopoietic Stem Cell Transplantation in Patients with Sickle Cell Disease
Hematopoietic stem cell transplantation (HSCT) is potentially curative for patients with sickle cell disease (SCD). Patients with stable donor engraftment after allogeneic HSCT generally do not experience SCD-related complications; however,…
Read More » -
Longitudinal Study of ICET-A on Glucose Tolerance, Insulin Sensitivity and β-cell Secretion in Eleven β-Thalassemia Major Patients With Mild Iron Overload
Background: Iron chelation therapy (ICT) is the gold standard for treating patients with iron overload, though its long-term effects are still under evaluation. According to current recommendations regarding transfusion-dependent (TD) β-thalassemia…
Read More »